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Abstract Highly adhesive glycoprotein von Willebrand
factor (VWF) multimer induces platelet aggregation and
leukocyte tethering or extravasation on the injured vascular
wall, contributing to microvascular plugging and inflam-
mation in brain ischemia–reperfusion. A disintegrin and
metalloproteinase with thrombospondin type-1 motifs 13
(ADAMTS13) cleaves the VWF multimer strand and
reduces its prothrombotic and proinflammatory functions.
Although ADAMTS13 deficiency is known to amplify
post-ischemic cerebral hypoperfusion, there is no report
available on the effect of ADAMTS13 on inflammation
after brain ischemia. We investigated if ADAMTS13
deficiency intensifies the increase of extracellular HMGB1,
a hallmark of post-stroke inflammation, and exacerbates
brain injury after ischemia–reperfusion. ADAMTS13 gene
knockout (KO) and wild-type (WT) mice were subjected to
30-min middle cerebral artery occlusion (MCAO) and
23.5-h reperfusion under continuous monitoring of regional
cerebral blood flow (rCBF). The infarct volume, plasma
high-mobility group box1 (HMGB1) level, and immuno-
reactivity of the ischemic cerebral cortical tissue (double
immunofluorescent labeling) against HMGB1/NeuN (neu-
ron-specific nuclear protein) or HMGB1/MPO (myeloper-
oxidase) were estimated 24 h after MCAO. ADAMTS
13KO mice had larger brain infarcts compared with WT
24 h after MCAO (p \ 0.05). The rCBF during reperfusion
decreased more in ADAMTS13KO mice. The plasma
HMGB1 increased more in ADAMTS13KO mice than in
WT after ischemia–reperfusion (p \ 0.05). Brain ischemia
induced more prominent activation of inflammatory cells
co-expressing HMGB1 and MPO and more marked neu-
ronal death in the cortical ischemic penumbra of ADAM-
TS13KO mice. ADAMTS13 deficiency may enhance
systemic and brain inflammation associated with HMGB1
neurotoxicity, and aggravate brain damage in mice after
brief focal ischemia. We hypothesize that ADAMTS13
protects brain from ischemia–reperfusion injury by regu-
lating VWF-dependent inflammation as well as microvas-
cular plugging.
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Introduction
The post-ischemic inflammation incites stroke evolution
[15, 16, 19–21, 32]. An ischemic insult triggers leukocytes
infiltration and astrocyte and microglia activations in the
affected brain, leading to the increase of the high-mobility
group box1 (HMGB1) in the plasma and brain of the stroke
model [19, 21]. The HMGB1 is a potent proinflammatory
cytokine secreted by blood-immune [23, 29, 45] and brain-
glial cells [35]. This extracellular HMGB1 further activates
monocytes/macrophages [3, 34], neutrophils [1, 34],
microvascular endothelial cells [12], astrocytes [36] and
microglia [24], amplifies the systemic and brain inflam-
mation, and extends the ischemic brain damage into the
penumbra [19, 21, 24, 27, 33, 38].
Within the ischemic brain vasculature after middle
cerebral artery occlusion (MCAO), circulating platelets [2,
28] and leukocytes [9, 28, 31] are activated, inducing
microvascular obstructions and inflammation. In the initial
activations of platelet and leukocyte on ischemic endo-
thelium, a large multimeric adhesive glycoprotein von
Willebrand factor (VWF) plays a central role. The VWF
multimer tethers platelets on the vascular endothelial sur-
face, leading to platelet activation [40]. This platelet-dec-
orated VWF multimer string bound to endothelium
supports leukocytes tethering, rolling and transmigration
on stimulated vascular endothelial cells, and links throm-
bosis to inflammation [5, 7, 37]. The platelet binding
affinity of VWF increases with increasing length of the
VWF multimer strand and with high fluid shear stress [40,
44]. Accordingly, the longest multimer termed ultra-large
VWF (ULVWF; secreted by vascular endothelium upon
stimulation) exerts its maximum prothrombotic and pro-
inflammatory functions in the microvasculture or stenotic
vessels under high shear stress condition [30, 40, 41, 43].
A disintegrin and metalloproteinase with thrombospon-
din type-1 motifs 13 (ADAMTS13) inhibits these VWF
functions by cleaving the Tyr1605–Met1606 bond in the
A2 domain of the VWF [13, 41]. Physiologically, circu-
lating ADAMTS13 cleaves the ULVWF secreted from
endothelial cells, releasing tethered platelets and VWF
fragments [11]. In a setting of on-going thrombus forma-
tion, the high shear stress induced at the stenotic vascula-
ture stretches plasma-derived VWF multimers (smaller
than ULVWF) on the thrombus surface. The extended
VWF multimers involved in the platelet thrombosis are
consequently cleaved by ADAMTS13 [41]. Notably, by
decreasing the interaction between the ULVWF–platelet
strands and leukocytes, ADAMTS13 reduces leukocytes
adhesion and extravasation on the stimulated vascular wall
and down-regulates tissue inflammation [5, 7, 37].
ADAMTS13 deficiency in humans increases the circulating
ULVWF resulting in thrombotic thrombocytopenic purpura
(TTP) [17, 41]. The TTP manifests fever and neurological
deficits associated with VWF–platelet microthrombus for-
mation in the brain. This implies that ADAMTS13 plays a
role in inflammation after brain ischemia in TTP patients.
Early studies have shown that ADAMTS13 deficiency
aggravates ischemic brain damage in experimental stroke
models [14, 48]. We revealed that in the ADAMTS13-
deficient mice after a brief focal ischemia the post-ischemic
hypoperfusion was significantly amplified partly because of
enhanced microvascular plugging by VWF–platelet–leu-
kocyte complex [14]. However, it still remains unclear if an
enhanced inflammatory reaction is involved in the deteri-
oration of ischemic brain injury under ADAMTS13 defi-
ciency. Here, we investigated whether ADAMTS13 gene
deletion intensifies the increase of extracellular HMGB1, a
hallmark of post-stroke inflammation, and exacerbates the
brain damage after ischemia–reperfusion.
Materials and methods
Animals
The effect of ADAMTS13 gene deletion on inflammation
after brain ischemia was investigated using male ADAM-
TS13KO and littermate WT mice in an SV129 genetic
background, originally generated as a TTP model by our
study group [4]. Studies using KO (n = 31) and WT
(n = 31) mice (8–10 weeks of age, 20–23 g of body
weight) were approved by the institutional ethics commit-
tee. The genotype of each animal was kept unspecified
until all experiment’s completion.
Middle cerebral artery occlusion
Thirty-minute MCAO by thread insertion from the com-
mon carotid artery was induced in KO (n = 21) and WT
(n = 21) mice as previously described [14, 19–21]. Mice
were anesthetized with 2% halothane for induction and
maintained on 1% halothane in 70% N2O and 30% O2 by
face mask. Body temperature was maintained at 36.5–
37.0C during surgery. Successful left MCAO was con-
firmed according to the following criteria: (1) rCBF in the
left cerebral cortex at the thread insertion less than 20%
of the pre-MCAO rCBF, and (2) consistent presence of
significant ischemic neurological symptoms of the left
cerebral hemisphere, characterized by right paresis and
right circling behavior, during 30-min MCAO. The MCAO
surgery was performed within 7 min without bleeding. The
anesthesia was discontinued during 30-min MCAO. There
were no statistically significant differences in body tem-
perature between the two groups immediately before or
after the thread insertion, or 10, 20, and 30 min after
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MCAO. The thread was removed under re-anesthesia after
30-min MCAO. Sham surgery in KO (n = 10) and WT
(n = 10) involved temporary insertion (1 s) of the thread
into the left common carotid artery without MCAO. There
were no statistical differences in prothrombin time or sur-
vival rate between KO and WT mice at 24 h after MCAO
(Table 1).
Regional cerebral blood flow
The rCBF was measured by laser Doppler flowmetry
(LDF) (ALF21, Advance Co., Tokyo, Japan) as previously
described [14, 20]. The LDF probe was placed through a
guide cannula into the left cerebral cortex stereotaxically
(0.22 mm posterior and 2.5 mm lateral from bregma;
1.5 mm depth from the skull surface) on a stereotaxic
instrument (Narishige Scientific Instrument Lab: SR-5 M,
Tokyo) under anesthesia (pentobarbital 50 mg/kg, i.p.)
24 h before MCAO or sham surgery. The rCBF was
monitored in all animals continuously from 30 min before
MCAO until immediately after reperfusion. In randomly
selected animals, the rCBF was repeatedly recorded over
time within 24 h after MCAO. The rCBF during occlusion
and reperfusion was expressed as percentages of the
preMCAO LDF baseline value.
Infarct volume and neurological deficit
The brains were sectioned coronally (four 2-mm thick
slices) according to a mouse brain matrix 24 h after MCAO
(KO, n = 14 and WT, n = 15) or sham operation (KO,
n = 5 and WT, n = 5). The infarct area was measured in
each slice stained with 2,3,5 triphenyltetrazolium chloride
with an image analysis system (NIH Image, version 1.63),
and the infarct volume was calculated [14, 19–21]. Neu-
rological deficit score ranging from 0 (normal motor
function) to 5 (no spontaneous motor activity) was mea-
sured at 24 h after MCAO [14, 19, 21] (Table 1).
Plasma HMGB1 measurement
The plasma HMGB1 protein was evaluated by western blot
24 h after MCAO. Plasma samples were fractionated by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis, and HMGB1 levels were determined by immu-
noblotting with respect to a standard curve, with
recombinant HMGB1 as a reference (Sigma-Aldrich,
Tokyo) [19, 21]. A blood sample (500 lL) was taken from
each experimental animal via inferior vena cava 24 h after
MCAO (KO, n = 11 and WT, n = 12) or sham surgery
(KO, n = 10 and WT, n = 10). The sample was centri-
fuged (3,000 rpm at 4C for 10 min), and the supernatant
(200 lL) was further centrifuged (15,000 rpm at 4C for
20 min). SDS sample buffer [125 mmol/L Tris (pH 6.8),
2% SDS, 20% glycerol, 0.0001% bromophenol blue, and
10% b-mercaptoethanol] (100 lL) was added to the plasma
extract solution (100 lL), and the resultant sample was
heated at 95C for 5 min. Protein (15 lg) was separated by
SDS–polyacrylamide gel electrophoresis (20% gel). Blot-
ting was performed at 2 mA/cm2 by semi-dry type blotting
(Bio-Rad, Tokyo, Japan). The blots were blocked with 5%
non-fat dry milk in Tris-buffered saline in 0.1% Tween 20
(TBS-T) at 4C and incubated with goat polyclonal anti-
HMGB1 primary antibody (1:200) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) in TBS-T, followed
by bovine anti-goat IgG (heavy chain and light chain
[H ? L]) alkaline phosphatase conjugate (1:1000) in
TBS-T. The blots were visualized with the use of alkaline
phosphatase color reagents. The signal intensity of the blots
was measured with an image analysis system (NIH Image,
version 1.63).
Double immunohistochemical staining for HMGB1/NeuN
and HMGB1/MPO
Double immunofluorescent labeling for HMGB1 with
NeuN or MPO on paraffin-embedded 5-lm coronal sections
Table 1 Effect of ADAMTS13 gene deletion on brain ischemia in mice after 30-min MCAO and 23.5-h reperfusion
WT KO
Brain infarct volume (mm3) 12.0 ± 2.0 (n = 15) p \ 0.05a 28.5 ± 5.8 (n = 14)
Neurological deficit score 1.3 ± 0.2 (n = 15) p \ 0.05a 1.9 ± 0.2 (n = 14)
Prothrombin time (s) 12.1 ± 0.8 (n = 7) ns 11.6 ± 0.9 (n = 6)
Survival rate (%) 95.2 (n = 20/21) ns 90.4 (n = 19/21)
The values are expressed as the mean ± SEM. Neurological deficit score, score 0; normal motor function, 1; flexion of torso and of contralateral
forelimb upon lifting of the animal by the tail, 2; circling to the ipsilateral side but normal posture at rest, 3; circling to the ipsilateral side, 4;
rolling to the ipsilateral side, 5; leaning to the ipsilateral side at rest (no spontaneous motor activity)
ns Statistically not significant
a Student t test
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of the mouse brain was analyzed by fluorescence micros-
copy (Nikon, AZ-FL, Tokyo, Japan). At 24 h after MCAO
(KO, n = 5; WT, n = 5) or sham surgery (KO, n = 5; WT,
n = 5), mice were humanely perfused transcardially with
saline and 4% paraformaldehyde. The brains were removed
of fat and water using an autodegreasing unit (RH-12;
Sakura Seiko Co, Tokyo) and embedded in paraffin. Sub-
sequently, 5-lm sections were mounted on slides and dried
at 37C for 1 day. After deparaffinization and rehydration,
the sections were incubated with primary antibodies of
biotinylated anti-mouse NeuN (1:200; Chemicon Interna-
tional, Temecula, CA, USA) or rabbit polyclonal anti-MPO
(1:200; DAKO Inc., Carpinteria, CA, USA) and of goat
polyclonal anti-HMGB1 (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) overnight at 4C. Sections were then
incubated with donkey anti-goat IgG-FITC secondary
antibody (1:200; Santa Cruz Biotechnology) for 1 h, and
thereafter with goat anti-rabbit IgG-Texas red secondary
antibody (1:200; Santa Cruz Biotechnology) or Ultra avi-
dine Texas Red (1:200; Leinco Technologies) for 1 h. The
sections were imaged and analyzed. The histological find-
ings were evaluated by neuropathologists until a consensus
was obtained. The fluorescence intensity (for cells positive
to NeuN, MPO, or HMGB1) in five randomly selected areas
(150 lm 9 200 lm for each) from the region of interest in
the ischemic cerebral cortex (as indicated in Figs. 2, 3) was
evaluated with an image analysis system (NIH Image, ver-
sion 1.63) with the corresponding non-ischemic contralat-
eral regions as a control, and the relative fluorescence
intensity was calculated. In ischemic stroke, the necrotic
core is surrounded by a zone of reactive/inflammatory
cytosis which can extend the initial insult into the penumbra
with delayed cell death. Based on this concept, the region of
interest in the cortical penumbra for the fluorescence eval-
uation was decided as indicated.
Statistical analysis
Data are presented as mean ± standard error of mean
(SEM). For multiple pairwise comparisons in parametric
analysis, two-way analysis of variance (ANOVA) followed
by Tukey–Kramer’s test was performed. When only two
groups were compared, Student’s t test was used. Probability
values of\0.05 were considered statistically significant.
Results
Brain infarction
The ADAMTS13 gene knockout (ADAMTS13KO) mice
group had a significantly larger volume of brain infarction
compared with the wild-type (WT) following 23.5-h
reperfusion after 30-min MCAO (Student’s t test) (Table 1).
No ischemic brain damage was observed in either KO or
WT mice after sham operation.
Neurological deficits
ADAMTS13KO mice had more severe neurological defi-
cits than the WT (Student’s t test) 24 h after MCAO
(Table 1).
Regional cerebral blood flow
The rCBF showed no statistical differences between the two
groups during MCAO or immediately after reperfusion.
However, the rCBF in ADAMTS13KO mice progressively
decreased significantly more markedly compared to WT
during the first 30-min reperfusion (Tukey–Kramer’s test).
24 h after MCAO, the rCBF in KO mice remained signifi-
cantly lower compared to WT (Student’s t test) (Table 2).
ADAMTS13 gene deletion enhances post-ischemic
increase of plasma HMGB1
A 30-min MCAO and 23.5-h reperfusion significantly
increased the plasma HMGB1 level both in ADAM-
TS13KO and WT mice as compared to sham operation
(Fig. 1). However, this increase of plasma HMGB1 after
MCAO was more markedly enhanced in ADAMTS13KO
mice than in WT (Tukey–Kramer’s test).
ADAMTS13 gene deletion intensifies post-ischemic
brain inflammation and neuronal death
Double immunohistochemical staining for HMGB1/NeuN
and HMGB1/MPO
The qualitative analysis of double immunofluorescent
labeling for HMGB1 with NeuN (neuron-specific nuclear
protein) or MPO (myeloperoxidase) on the cortical tissue
24 h after MCAO or sham operation showed that (1) the
number of neurons immunoreactive to NeuN in the ische-
mic penumbra decreased more in ADAMTS13KO mice
compared to WT (Fig. 2), (2) HMGB1 immunoreactivity
disappeared in the ischemic neuronal nuclei in both KO
and WT mice, suggestive of a translocation of HMGB1
from neuronal nucleus either to neuronal cytoplasm or to
extracellular space (Fig. 2), and (3) cells with co-expres-
sion of MPO (a marker for neutrophils, macrophages and/
or microglia) and HMGB1 appeared more prominently in
the ischemic penumbra in ADAMTS13KO mice than in
WT (Fig. 3).
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Relative fluorescent intensity of NeuN, MPO and HMGB1
The relative fluorescent intensity (%) in the ischemic
cerebral cortex 24 h after MCAO was significantly
decreased for NeuN in ADAMTS13KO mice compared to
WT [57.5 ± 8.7 in KO vs. 93.2 ± 5.5 in WT (p \ 0.05,
student’s t test)], and increased for both MPO and HMGB1
more in ADAMTS13KO mice than in WT [KO vs. WT:
557.7 ± 139.8 vs. 310.4 ± 131.7 for MPO, and 159.7 ±
46.5 vs. 70.2 ± 35.1 for HMGB1 (although not statistically
significant)].
Discussion
The (UL)VWF, the substrate of ADAMTS13, recruits
platelets and leukocytes onto the injured vascular endo-
thelium, and mediates microvascular plugging and enhan-
ces the tissue inflammation [5, 7, 30, 37, 40, 41, 43, 44].
ADAMTS13 inhibits these prothrombotic and proinflam-
matory functions of (UL)VWF [7, 13, 41]. Our current
study implies that ADAMTS13 gene deletion amplifies
systemic and brain inflammatory responses against brain
ischemia–reperfusion enhancing a potent cytokine HMGB1
neurotoxicity, leads to progressive decline of post-ischemic
cerebral blood reflow, and exacerbates ischemic brain
injury. ADAMTS13 may play a neuroprotective role
against inflammation in ischemic stroke.
ADAMTS13 deficiency may promote inflammation by
activating platelets, leukocytes, and vascular endothelium
after brain ischemia–reperfusion. Responding to ischemia–
reperfusion, the stimulated vascular endothelial cells
secrete ULVWF [44]. Binding of VWF to the platelet
membrane glycoprotein initiates a signaling cascade that
causes platelet activation [25, 46]. The activated plate-
lets release multiple proinflammatory factors, mitogenic
mediators, metalloproteinases, and reactive oxygen spe-
cies, and stimulate the leukocytes and endothelium to incite
inflammatory reactions [8, 10]. Further, the platelet–
(UL)VWF string directly supports the leukocyte transmi-
gration into the inflammatory tissue [5, 7, 37]. Thus, the
VWF-cleaving protease ADAMTS13 plays a role as an
anti-inflammatory factor, and therefore its deficiency can
exaggerate the post-ischemic inflammation.
In ADAMTS13KO mice after a cerebral ischemia, the
plasma HMGB1 increased more and the HMGB1-
expressing immune cells appeared more prominent in the
cortical penumbra than in WT. The increased extracellular
HMGB1 may contribute to secondary ischemic brain
damage in ADAMTS13KO mice. The HMGB1, a DNA-
binding protein, is a central proinflammatory cytokine [29].
Upon inflammatory signals, the chromosomal HMGB1
relocates into cytoplasmic secretory lysosomes and is
secreted into the immunological synapse [29] or into the
extracellular space by monocytes/macrophages [45], neu-
trophils [23], mature dendritic cells [29], natural killer cells
Table 2 Effect of ADAMTS13 gene deletion on regional cerebral
blood flow (rCBF) in mice of 30-min MCAO model
WT (n = 6) KO (n = 7)
Time (min)
Baseline 100.0 ± 0 ns 100.0 ± 0
0 13.6 ± 4.6 ns 13.2 ± 2.0
10 17.9 ± 3.4 ns 22.4 ± 6.3
20 17.7 ± 5.2 ns 19.3 ± 5.7
30 16.8 ± 4.7 ns 18.6 ± 3.5
Reperfusion 114.3 ± 19.1 ns 88.1 ± 8.1
40 90.5 ± 12.7 p \ 0.05a 48.4 ± 8.4
50 93.8 ± 11.3 p \ 0.01a 35.4 ± 7.7
60 83.2 ± 6.8 p \ 0.01a 28.1 ± 4.7
Time (hour)
24 72.9 ± 13.9 p \ 0.05b 37.2 ± 5.9
rCBF values are expressed as the mean ± SEM (% of baseline)
a Turkey-Kramer’s test after two-way repeated measures ANOVA
[F(8,98) = 5.841, p \ 0.0001)]
b Student’s t test
Fig. 1 Effect of ADAMTS13 gene deletion on plasma HMGB1 in
mice after 30-min MCAO. The plasma HMGB1 protein was
evaluated by western blot. Transient focal ischemia of 30-min
MCAO followed by 23.5-h reperfusion significantly increased the
plasma HMGB1 level both in ADAMTS13KO and WT mice when
compared to sham operation [plasma HMGB1 (ng/ml): MCAO-KO;
34.4 ± 5.3 vs. sham-KO; 3.8 ± 1.2, p \ 0.01, and MCAO-WT;
19.6 ± 3.5 vs. sham-WT; 4.5 ± 1.7, p \ 0.05, Tukey–Kramer’s test
after two-way ANOVA (F (1,40) = 38.401, p \ 0.01)]. This increase
of plasma HMGB1 at 24 h after MCAO was more markedly enhanced
in ADAMTS13KO mice than in WT [MCAO-KO; 34.4 ± 5.3 vs.
MCAO-WT; 19.6 ± 3.5, p \ 0.05, Tukey–Kramer’s test after two-
way ANOVA (F(1,40) = 4.296, p \ 0.05)]. Sham-WT n = 10,
Sham-KO n = 10, MCAO-WT n = 12, MCAO-KO n = 11. Values
are expressed as the mean ± SEM. *p \ 0.05, **p \ 0.01, Tukey–
Kramer’s test after two-way ANOVA
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[29], and glia [35]. HMGB1 also leaks from necrotic cells
[42] and ischemic neurons [38]. The extracellular HMGB1
binds to its receptors, RAGE (receptor for advanced gly-
cation end products) [22], Toll-like receptor 2 (TLR2), and
TLR4 [34], recapitulates the intracellular signaling cas-
cades initiated by early proinflammatory stresses, and thus
propagates continuous proinflammatory responses [3, 22,
29, 34, 42]. Naturally, high blood HMGB1 correlates with
the severity of systemic inflammation [29, 45].
After brain ischemia, extracellular HMGB1 increases
rapidly in the blood and central nervous system, and
induces neuroinflammation [24, 38]. HMGB-1 early
released from the striatal ischemic core can bind to RAGE
that is robustly expressed in the peri-infarct region, and
extend the ischemic brain injury [38]. HMGB1-RAGE
signaling in infiltrating macrophages and activated
microglia seemingly mediate neuronal death evolution in
the ischemic penumbra [33]. The HMGB1 inhibition in the
brain or systemic circulation protects the blood–brain
barrier and the brain from ischemia [24, 27, 33, 47].
Inhibition of leukocytes and microglia results in decreased
HMGB1 levels in the brain and plasma, reduces apoptosis
in the ischemic brain, and improves brain atrophy and
neurologic deficits [19, 21]. Therefore, the increased
extracellular HMGB1 in the blood and brain of ADAM-
TS13KO mice as observed in our study can exacerbate
ischemic brain injury by intensifying systemic and brain
inflammation. Interestingly, the platelet intracellular
HMGB1 is exported to the external surface of the plasma
membrane upon its activation [39]. Accordingly, the acti-
vated platelet may be an additional source of the exceed-
ingly increased plasma HMGB1 in ADAMTS13KO mice
after brain ischemia, where enhanced VWF–platelet inter-
actions develop [14]. We suggest that ADAMTS13 defi-
ciency multiplies secondary insults after brain ischemia by
up-regulating (UL)VWF-mediating inflammation and
enhancing HMGB1 neurotoxicity in the systemic and local
environments.
This study suggests a potential therapy with ADAM-
TS13 for acute ischemic stroke by breaking a vicious circle
Fig. 2 Effect of ADAMTS13 gene deletion on NeuN positive cells
expressing HMGB1 in mice brain after 30-min MCAO. Qualitative
analysis of double immunofluorescent labeling for HMGB1 with
NeuN on the brain tissue 24 h after MCAO showed that the number of
neurons immunoreactive to NeuN in the ischemic cortical penumbra
decreased more in ADAMTS13KO mice than WT. The HMGB1
immunoreactivity disappeared in the ischemic neuronal nuclei in both
KO and WT mice, suggesting that neuronal-nuclear HMGB1
translocated into either the neuronal cytoplasm or the extracellular
space. In addition, the HMGB1 immunoreactivity seemed to increase
in the ischemic cortical tissue in the ADAMTS13KO mice, indicating
a possibility that non-neuronal HMGB1 positive cells were activated
in the KO mice compared to the WT (n = 5 in each group). Scale bar
50 lm. NeuN positive cells red, HMGB1 positive cells green, merge
yellow
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of thrombosis and inflammation. The (UL)VWF–platelet
string interacts with leukocytes, and provokes inflamma-
tion [5, 7, 37]. The inflammation induces the endothelial-
ULVWF secretion [44]. The proinflammatory cytokines
from leukocytes and endothelial cells [such as tumor
necrosis factor (TNF)-a and interleukin (IL)-8] stimulate
the endothelial ULVWF release and IL-6 protects the
ULVWF from cleavage [6]. This would increase the
number of ULVWF multimers in plasma sufficiently to
aggregate platelets and on vascular endothelial surface to
tether platelets and leukocytes onto the endothelium,
providing a linkage between thrombosis and inflammation.
Of note, HMGB1 stimulates the monocytes/macrophages
[3, 34], neutrophils [1, 34] and glial cells [24, 36, 38] to
produce TNF-a, IL-1, IL-6 and/or IL-8, and incites the
microvascular endothelial cells [12, 38] to express TNF-a,
IL-8 and various adhesion molecules. Namely, the increased
plasma HMGB1 in ADAMTS13-deficient mice can upreg-
ulate ULVWF, and thus reinforce the association between
inflammation and thrombosis. ADAMTS13 may prevent
stroke evolution by interfering with the crosstalk between
thrombosis and inflammation.
Thrombolytic therapy using tissue plasminogen activator
(tPA) for acute stroke has limitations in the therapeutic time
window and in the drug dosage due to the risk of hemorrhagic
transformation [18]. Further, tPA directly exerts neurotox-
icity in the ischemic brain [26]. We suggest that a regulation
of the interaction between (UL)VWF–platelet and leukocyte
using ADAMTS13 may become a novel therapeutic option
in acute brain ischemia. ADAMTS13 does not dissolve
the VWF–platelet–primary hemostatic thrombus in the
absence of pathologically high fluid shear stress. Therefore,
ADAMTS13 may be particularly well suited for acute
ischemic stroke without increasing hemorrhagic complica-
tions. An early experimental study [48] together with our
preliminary data (not shown) demonstrated that recombinant
human ADAMTS13 administration reduced infarct volume
in stroke model in a VWF-dependent manner without
producing cerebral hemorrhage.
This study has several limitations. For example, the
reduction of cerebral blood reflow in ADAMTS13KO mice
after ischemic insult was continuous and higher than that
observed in WT. Therefore, even without the amplified
inflammation with HMGB1 neurotoxic effects, only the
difference in the blood flow recovery might explain the
following more deleterious events in the ischemic brain
of ADAMTS13-deficient mice compared to WT. The
enhanced elevation of the plasma HMGB1 under ADAM-
TS13 deficiency after brain ischemia might be also
explained simply by the more exacerbated brain damage,
regardless of the theoretically intensified interactions
between the platelet–(UL)VWF strands and the leukocytes
without VWF cleaving protease. The future study required
to clarify these issues would include chronological data
Fig. 3 Effect of ADAMTS13
gene deletion on MPO positive
cells expressing HMGB1 in
mice brain after 30-min MCAO.
Qualitative analysis of double
immunofluorescent labeling for
HMGB1 with MPO on the brain
tissue 24 h after MCAO showed
that cells co-expressing MPO
and HMGB1 were more
prominent in the ischemic
cortical penumbra in KO mice
than in WT (n = 5 in each
group). Scale bar 50 lm. MPO
positive cells red, HMGB1
positive cells green, merge
yellow
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evaluations in the stroke experiments with permanent
ischemic procedure (deleting the reperfusion effect) or with
enhancing/inhibiting HMGB1 activities by drugs or genetic
manipulations.
Conclusions
A gene deletion of ADAMTS13 renders mice more vul-
nerable to brain ischemia–reperfusion injury than their
wild-type counterparts, when subjected to 30-min MCAO.
This preliminary study suggests that ADAMTS13 defi-
ciency may exacerbate systemic and neuronal inflamma-
tion after brain ischemia via VWF-dependent pathway,
although this remains still hypothetical. Further studies are
warranted to better characterize the role of ADAMTS13 in
brain ischemia–reperfusion and to provide a novel thera-
peutic approach for ischemic stroke by regulating VWF-
dependent inflammation as well as microvascular plugging.
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